Breaking News

Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer U.S. Small Business Administration Applications are Required before FEMA Individual Assistance can be Provided Apply for Assistance Even If You Are Unsure Department of Labor cites Dollar Tree again for endangering workers, continuing company’s lengthy history of workplace safety violations False Name Turns into Counterfeit U.S. Currency Discovery by Wellesley Island Border Patrol Agents Administrator Samantha Power Meets with Foreign Minister of Sri Lanka Ali Sabry | Readout FIS Challenges Nearly 200 Startups to Pitch their Boldest Ideas in First APAC Fintech Competition READOUT: Deputy Undersecretary Lee visits Colombia, engages with new Petro administration leaders on labor compliance under trade agreement

Issued: Friday 30 January 2009, London, UK & Philadelphia, US

GlaxoSmithKline (GSK) today announced that Deirdre Connelly will join the company as President, North American Pharmaceuticals, effective Monday 9 February 2009.  She will report to Andrew Witty, Chief Executive Officer and become a member of GSK’s Corporate Executive Team.

Andrew Witty, Chief Executive Officer, said, “GSK’s US pharmaceuticals business is a critical component of our strategy and future performance. It is also operating in a highly competitive and rapidly changing environment. As an accomplished senior leader within our industry, Deidre is somebody who truly understands the needs of patients and our customers and can drive the efforts we are making to reshape this business and improve future growth. I look forward to welcoming her to GSK and the Corporate Executive Team.”

Deirdre was appointed President of US operations at Eli Lilly and Company in 2005. 

She joined Lilly in 1983 as a sales representative and has held sales and marketing roles of increasing responsibility. In 2003, she became executive director of human resources for Eli Lilly’s US affiliate.

Notes to Editors


Deirdre was appointed President of US operations at Eli Lilly and Company in 2005.  Previously she was senior vice president for Human Resources for Lilly.  She had joined Lilly in 1983 as a sales representative and moved to San Juan as a marketing associate a year later.  After progressing through sales and marketing roles of increasing responsibility, including Lilly’s international management development program, she was promoted to General Manager for Eli Lilly Puerto Rico, SA, in 1995.

From 1997 to 2001, she held positions of regional sales director, executive director of global marketing for Evista, (an osteoporosis treatment for post-menopausal women) and was promoted to leader of the woman’s health business unit in the US affiliate. In 2003, she became executive director of human resources for the US affiliate, joining the company’s policy committee in 2004.

A native of San Juan, Deirdre received a bachelor’s degree in economics and marketing from Lycoming College in Pennsylvania in 1983. She graduated from the Harvard University’s Advanced Management Program in 2000.   Deirdre is a member of the Board of Directors of Macy’s Inc., the US department store chain.  

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit



UK Media enquiries:

Philip Thomson

(020) 8047 5502


Alice Hunt

(020) 8047 5502


David Outhwaite

(020) 8047 5502


Stephen Rea

(020) 8047 5502




US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Kevin Colgan

(919) 483 2839


Sarah Alspach

(215) 751 7709



European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564


Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503


US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jen Hill

(215) 751 7002

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual Report on Form 20-F for 2007.

Source link